Cargando…

Pharmaceutical Equivalence of Distributed Generic Antiretroviral (ARV) in Asian Settings: The Cross-Sectional Surveillance Study – PEDA Study

OBJECTIVES: Ensuring that medicines meet quality standards is mandatory for ensuring safety and efficacy. There have been occasional reports of substandard generic medicines, especially in resource-limiting settings where policies to control quality may be less rigorous. As HIV treatment in Thailand...

Descripción completa

Detalles Bibliográficos
Autores principales: Sapsirisavat, Vorapot, Vongsutilers, Vorasit, Thammajaruk, Narukjaporn, Pussadee, Kanitta, Riyaten, Prakit, Kerr, Stephen, Avihingsanon, Anchalee, Phanuphak, Praphan, Ruxrungtham, Kiat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913952/
https://www.ncbi.nlm.nih.gov/pubmed/27322409
http://dx.doi.org/10.1371/journal.pone.0157039
_version_ 1782438484532789248
author Sapsirisavat, Vorapot
Vongsutilers, Vorasit
Thammajaruk, Narukjaporn
Pussadee, Kanitta
Riyaten, Prakit
Kerr, Stephen
Avihingsanon, Anchalee
Phanuphak, Praphan
Ruxrungtham, Kiat
author_facet Sapsirisavat, Vorapot
Vongsutilers, Vorasit
Thammajaruk, Narukjaporn
Pussadee, Kanitta
Riyaten, Prakit
Kerr, Stephen
Avihingsanon, Anchalee
Phanuphak, Praphan
Ruxrungtham, Kiat
author_sort Sapsirisavat, Vorapot
collection PubMed
description OBJECTIVES: Ensuring that medicines meet quality standards is mandatory for ensuring safety and efficacy. There have been occasional reports of substandard generic medicines, especially in resource-limiting settings where policies to control quality may be less rigorous. As HIV treatment in Thailand depends mostly on affordable generic antiretrovirals (ARV), we performed quality assurance testing of several generic ARV available from different sources in Thailand and a source from Vietnam. METHODS: We sampled Tenofovir 300mg, Efavirenz 600mg and Lopinavir/ritonavir 200/50mg from 10 primary hospitals randomly selected from those participating in the National AIDS Program, 2 non-government organization ARV clinics, and 3 private drug stores. Quality of ARV was analyzed by blinded investigators at the Faculty of Pharmaceutical Science, Chulalongkorn University. The analysis included an identification test for drug molecules, a chemical composition assay to quantitate the active ingredients, a uniformity of mass test and a dissolution test to assess in-vitro drug release. Comparisons were made against the standards described in the WHO international pharmacopeia. RESULTS: A total of 42 batches of ARV from 15 sources were sampled from January–March 2015. Among those generics, 23, 17, 1, and 1 were Thai-made, Indian-made, Vietnamese-made and Chinese-made, respectively. All sampled products, regardless of manufacturers or sources, met the International Pharmacopeia standards for composition assay, mass uniformity and dissolution. Although local regulations restrict ARV supply to hospitals and clinics, samples of ARV could be bought from private drug stores even without formal prescription. CONCLUSION: Sampled generic ARVs distributed within Thailand and 1 Vietnamese pharmacy showed consistent quality. However some products were illegally supplied without prescription, highlighting the importance of dispensing ARV for treatment or prevention in facilities where continuity along the HIV treatment and care cascade is available.
format Online
Article
Text
id pubmed-4913952
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-49139522016-07-06 Pharmaceutical Equivalence of Distributed Generic Antiretroviral (ARV) in Asian Settings: The Cross-Sectional Surveillance Study – PEDA Study Sapsirisavat, Vorapot Vongsutilers, Vorasit Thammajaruk, Narukjaporn Pussadee, Kanitta Riyaten, Prakit Kerr, Stephen Avihingsanon, Anchalee Phanuphak, Praphan Ruxrungtham, Kiat PLoS One Research Article OBJECTIVES: Ensuring that medicines meet quality standards is mandatory for ensuring safety and efficacy. There have been occasional reports of substandard generic medicines, especially in resource-limiting settings where policies to control quality may be less rigorous. As HIV treatment in Thailand depends mostly on affordable generic antiretrovirals (ARV), we performed quality assurance testing of several generic ARV available from different sources in Thailand and a source from Vietnam. METHODS: We sampled Tenofovir 300mg, Efavirenz 600mg and Lopinavir/ritonavir 200/50mg from 10 primary hospitals randomly selected from those participating in the National AIDS Program, 2 non-government organization ARV clinics, and 3 private drug stores. Quality of ARV was analyzed by blinded investigators at the Faculty of Pharmaceutical Science, Chulalongkorn University. The analysis included an identification test for drug molecules, a chemical composition assay to quantitate the active ingredients, a uniformity of mass test and a dissolution test to assess in-vitro drug release. Comparisons were made against the standards described in the WHO international pharmacopeia. RESULTS: A total of 42 batches of ARV from 15 sources were sampled from January–March 2015. Among those generics, 23, 17, 1, and 1 were Thai-made, Indian-made, Vietnamese-made and Chinese-made, respectively. All sampled products, regardless of manufacturers or sources, met the International Pharmacopeia standards for composition assay, mass uniformity and dissolution. Although local regulations restrict ARV supply to hospitals and clinics, samples of ARV could be bought from private drug stores even without formal prescription. CONCLUSION: Sampled generic ARVs distributed within Thailand and 1 Vietnamese pharmacy showed consistent quality. However some products were illegally supplied without prescription, highlighting the importance of dispensing ARV for treatment or prevention in facilities where continuity along the HIV treatment and care cascade is available. Public Library of Science 2016-06-20 /pmc/articles/PMC4913952/ /pubmed/27322409 http://dx.doi.org/10.1371/journal.pone.0157039 Text en © 2016 Sapsirisavat et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Sapsirisavat, Vorapot
Vongsutilers, Vorasit
Thammajaruk, Narukjaporn
Pussadee, Kanitta
Riyaten, Prakit
Kerr, Stephen
Avihingsanon, Anchalee
Phanuphak, Praphan
Ruxrungtham, Kiat
Pharmaceutical Equivalence of Distributed Generic Antiretroviral (ARV) in Asian Settings: The Cross-Sectional Surveillance Study – PEDA Study
title Pharmaceutical Equivalence of Distributed Generic Antiretroviral (ARV) in Asian Settings: The Cross-Sectional Surveillance Study – PEDA Study
title_full Pharmaceutical Equivalence of Distributed Generic Antiretroviral (ARV) in Asian Settings: The Cross-Sectional Surveillance Study – PEDA Study
title_fullStr Pharmaceutical Equivalence of Distributed Generic Antiretroviral (ARV) in Asian Settings: The Cross-Sectional Surveillance Study – PEDA Study
title_full_unstemmed Pharmaceutical Equivalence of Distributed Generic Antiretroviral (ARV) in Asian Settings: The Cross-Sectional Surveillance Study – PEDA Study
title_short Pharmaceutical Equivalence of Distributed Generic Antiretroviral (ARV) in Asian Settings: The Cross-Sectional Surveillance Study – PEDA Study
title_sort pharmaceutical equivalence of distributed generic antiretroviral (arv) in asian settings: the cross-sectional surveillance study – peda study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913952/
https://www.ncbi.nlm.nih.gov/pubmed/27322409
http://dx.doi.org/10.1371/journal.pone.0157039
work_keys_str_mv AT sapsirisavatvorapot pharmaceuticalequivalenceofdistributedgenericantiretroviralarvinasiansettingsthecrosssectionalsurveillancestudypedastudy
AT vongsutilersvorasit pharmaceuticalequivalenceofdistributedgenericantiretroviralarvinasiansettingsthecrosssectionalsurveillancestudypedastudy
AT thammajaruknarukjaporn pharmaceuticalequivalenceofdistributedgenericantiretroviralarvinasiansettingsthecrosssectionalsurveillancestudypedastudy
AT pussadeekanitta pharmaceuticalequivalenceofdistributedgenericantiretroviralarvinasiansettingsthecrosssectionalsurveillancestudypedastudy
AT riyatenprakit pharmaceuticalequivalenceofdistributedgenericantiretroviralarvinasiansettingsthecrosssectionalsurveillancestudypedastudy
AT kerrstephen pharmaceuticalequivalenceofdistributedgenericantiretroviralarvinasiansettingsthecrosssectionalsurveillancestudypedastudy
AT avihingsanonanchalee pharmaceuticalequivalenceofdistributedgenericantiretroviralarvinasiansettingsthecrosssectionalsurveillancestudypedastudy
AT phanuphakpraphan pharmaceuticalequivalenceofdistributedgenericantiretroviralarvinasiansettingsthecrosssectionalsurveillancestudypedastudy
AT ruxrungthamkiat pharmaceuticalequivalenceofdistributedgenericantiretroviralarvinasiansettingsthecrosssectionalsurveillancestudypedastudy
AT pharmaceuticalequivalenceofdistributedgenericantiretroviralarvinasiansettingsthecrosssectionalsurveillancestudypedastudy